Non selective beta blockers in cirrhosis/Reply to: “Non selective beta blockers in cirrhosis”

Mandorfer and Reiberger respond to the study regarding on the use of non selective β blockers (NSBB) in patients with cirrhosis. Carvedilol has not been properly compared to the current standard of care (NSBB plus endoscopic variceal ligation [EVL]) for the secondary prophylaxis of variceal bleeding. Thus, in accordance with recommendations by the Baveno VI faculty and the American Association for the Study of Liver Diseases, carvedilol is currently not recommended for secondary prophylaxis. They concluded that carvedilol is not harmful in patients with cirrhosis and ascites.